Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

Summary Background Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17–22 weeks. We assessed dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain. Methods We undertook a multicent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2012-11, Vol.13 (11), p.1087-1095
Hauptverfasser:	Long, Georgina V, Dr, Trefzer, Uwe, MD, Davies, Michael A, MD, Kefford, Richard F, Prof, Ascierto, Paolo A, MD, Chapman, Paul B, MD, Puzanov, Igor, MD, Hauschild, Axel, MD, Robert, Caroline, PhD, Algazi, Alain, MD, Mortier, Laurent, Prof, Tawbi, Hussein, PhD, Wilhelm, Tabea, MD, Zimmer, Lisa, MD, Switzky, Julie, MSN, Swann, Suzanne, PhD, Martin, Anne-Marie, PhD, Guckert, Mary, MSN, Goodman, Vicki, MD, Streit, Michael, MD, Kirkwood, John M, Prof, Schadendorf, Dirk, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Brain Neoplasms - drug therapy Brain Neoplasms - epidemiology Brain Neoplasms - secondary Chemotherapy Disease control Disease-Free Survival Female Hematology, Oncology and Palliative Medicine Humans Imidazoles - administration & dosage Imidazoles - adverse effects Immunotherapy Male Melanoma Melanoma - drug therapy Melanoma - epidemiology Melanoma - pathology Metastasis Middle Aged Monoclonal antibodies Mutation Neoplasm Staging Oximes - administration & dosage Oximes - adverse effects Patients Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!